Clinical Oncology PET Atlas PET and CT and MRI

Author: [UK] H.Bender
Publisher:
Publish Date: 2002-12-24
Features: Over the past 10 years, positron emission tomography (PET) has been applied to the clinical treatment of various malignant tumors, such as head and neck cancer, malignant melanoma, colon cancer, cecal cancer, lung cancer, breast cancer, and lymphoma. Studies have proven that PET can significantly alter the clinical treatment plans of many patients and can also reduce medical expenses by correcting tumor staging. In addition to staging tumors through whole-body imaging, PET can also detect the activity of tumors after chemotherapy, providing valuable data for clinicians to formulate further treatment plans, something other techniques cannot achieve. The author of this atlas has persistently explored PET examination techniques and challenges, accumulating extensive experience in the clinical application of PET. If nuclear medicine professionals refer to standard imaging results and classify them as malignant, suspicious, or non-specific glucose metabolism regions, fluorine-18 deoxyglucose PET (FDG PET) exhibits high sensitivity and acceptable specificity. This atlas aims to help nuclear medicine and imaging medicine professionals solve typical diagnostic problems encountered during their early stages of learning. Based on the author's experience, combining PET images with CT, MRI, and histopathology is essential, not only to obtain useful information about patients but also to understand the advantages and limitations of PET. This book also highlights the research results of PET as a functional imaging technology for general doctors, oncologists, and tumor surgeons, serving as a reference for experts. We believe that with the development of new radiopharmaceuticals to improve the accuracy of diagnosis and tumor staging, the application of PET will become increasingly widespread.